Silk Road Medical, Inc (SILK)

Silk Road Medical, Inc (SILK) — VMCI valuation read

Composite valuation read on SILK: VMCI 39/100 against a Healthcare sector median of 50. The 11-point below-median print is the headline number for Silk Road Medical, Inc, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for SILK: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on SILK: SILK trades at 23.0x earnings, 28% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -0.3x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

SILK fell 0.9% over the trailing 7 days, with a -5.5% read on a 30-day basis.